Capricor Therapeutics (CAPR) Stock Price & Analysis
Score
AI Analysis
SnapshotCapricor Therapeutics doesn’t screen as a clean setup today — Stocklytics 68/100 leaves more to prove. Under the hood: revenue compounding ~258% annually over recent years.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Capricor Therapeutics, Inc. (CAPR) last printed $9.53. Equity value is $551.90M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $3.19M | $2.67M | $1.67M | $1.01M | $310,250.00 | $244,898.00 | $2.55M | $25.18M | $22.27M | $0.00 |
About
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.